Results 191 to 200 of about 5,269,973 (298)
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim +17 more
wiley +1 more source
The Role of Serendipity in Scientific Discovery
In this lecture, Professor Matthew Bailes explores the fascinating role of serendipity in scientific discovery, sharing personal stories and insights from his groundbreaking research.
Matthew Bailes
core +1 more source
NMR-based platform for fragment-based lead discovery used in screening BRD4-targeted compounds. [PDF]
Yu JL +9 more
europepmc +1 more source
Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim +11 more
wiley +1 more source
Targeting host integrated stress response: lead discovery of flavonoid compounds active against coronaviruses PEDV and PDCoV. [PDF]
Yi L +6 more
europepmc +1 more source
A ligand-observed mass spectrometry approach integrated into the fragment based lead discovery pipeline. [PDF]
Chen X +9 more
europepmc +1 more source
Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba +5 more
wiley +1 more source
Cytochrome P450 Enzyme Metabolites in Lead Discovery and Development. [PDF]
Kandel SE, Wienkers LC, Lampe JN.
europepmc +1 more source
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David +12 more
wiley +1 more source

